
TNXP
Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company's commercial products include TONMYA, a centrally acting non-opioid analgesic small molecule approved for fibromyalgia in adults, as well as two FDA-approved migraine products: Zembrace SymTouch and Tosymra, both sumatriptan formulations. Tonix maintains a diversified pipeline of development and discovery-stage candidates alongside its commercial platform capabilities in sales, marketing, market access, and distribution.